Genzyme Co-Pay Assistance Program

The Genzyme Co-Pay Assistance Program helps eligible individuals in the United States who are prescribed treatment with Lumizyme® (alglucosidase alfa) pay for their eligible out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including co-pays, co-insurance and deductibles, regardless of financial status.

Once enrolled in Genzyme's Co-Pay Assistance Program, Genzyme will cover 100% of your eligible out-of-pocket Lumizyme drug and infusion-related costs up to the program maximum.

Once approved for assistance, your healthcare provider will be provided with information about your enrollment in this program along with directions on how to submit a claim to the Genzyme Co-Pay Assistance Program.

Who is eligible for the Genzyme Co-Pay Assistance Program?

Regardless of financial status, the program is open to individuals who:

  • Have primary commercial insurance
  • Are prescribed treatment with Lumizyme
  • Are enrolled in Genzyme's Charitable Access Program

You are NOT eligible if you:

  • Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
    • Medicare
    • Medicare Advantage Plans
      (Example: FreedomBlue offered through Blue Cross Blue Shield)
    • Medicare Part D
    • Medicaid
    • Medigap
    • Veterans Affairs, Department of Defense or TRICARE
    • In accordance with State law, the Program does not reimburse infusion-related charges for patients residing in Massachusetts, Michigan, Minnesota and Rhode Island.

Genzyme reserves the right to make eligibility determinations, to set program benefit maximums, to monitor participation, and to modify or discontinue the program at any time. This program assists patients with their out-of-pocket drug and infusion-related costs of Lumizyme only, not the cost of MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, pre-medications/other medications, Epi pens, transportation or other related services.

How to get started:

You complete the program application

Simply complete the online application available here.

Helpful information to have on hand when you apply:

  • Your treating Physician's contact information
  • Your health insurance card

You can also call your Genzyme Case Manager directly to learn more about the program and application process at 1-800-745-4447, Option 3

Your eligibility is verified

Your application will be reviewed for eligibility.

If you are eligible, you will be automatically enrolled in the program. Enrollment in the program is subject to confirmation of eligibility. 

You're enrolled!

Once approved, you will receive a confirmation letter and an enrollment card within 7-10 days. Contact your Genzyme Case Manager if you do not receive this confirmation. 

Your doctor or specialty pharmacy will receive a phone call with instructions on how to submit claims for reimbursement through the program.

Your enrollment in the program is effective from the date of approval through the end of the calendar year (calendar year is January 1 through December 31). 

If you are currently enrolled in our Co-Pay Assistance Program you will be automatically enrolled in the program for the next calendar year (January 1 through December 31) unless you decide to opt out of the program or your insurance coverage changes. 


LUMIZYME® (alglucosidase alfa) is an enzyme replacement therapy for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).


  • If you or your child is taking Lumizyme, you should know that severe and potentially life-threatening allergic-type reactions known as anaphylaxis or severe hypersensitivity reactions, and other severe reactions related to the immune system may occur during and after Lumizyme treatment. Reactions may include, for example, kidney dysfunction, extreme difficulty breathing, shallow breathing, abnormal heart rate, low blood pressure, or throat tightness (including face, tongue and lip swelling) and skin lesions.
  • If you or your child experiences these severe reactions, you may require close observation during and after Lumizyme administration. You should discuss with your physician the signs and symptoms of anaphylaxis and hypersensitivity reactions and seek immediate medical care should they occur. Anaphylaxis or severe hypersensitivity reactions are potentially very dangerous. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered when you are being infused with Lumizyme.
  • If your child has a current respiratory condition or illness and has compromised breathing or heart function due to Pompe disease, there may be risk of acute worsening of heart and/or lung function with Lumizyme due to the fluid of the infusion, and your doctor may decide that close observation during and after Lumizyme administration may be necessary.


Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide you with immediate medical care. Appropriate medical support and monitoring measures should be available during infusion.

Immune-Mediated Reactions: You or your child may be monitored for the development of systemic immune-mediated reactions while receiving Lumizyme. If these reactions occur, your doctor may discontinue the infusion and initiate appropriate medical treatment.

Risk of Acute Cardiorespiratory Failure: Infant Pompe patients with heart or breathing problems who are experiencing an acute respiratory condition may be at risk for increasing the seriousness of these problems as a result of Lumizyme administration due to the infusion fluid, and your child’s doctor may require additional monitoring for these infants.

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for Lumizyme infusion. Ventricular arrhythmias and slow heart rate resulting in cardiac arrest or death have been observed in infant Pompe patients with cardiac hypertrophy during general anesthesia for central venous catheter placement. Appropriate medical support and monitoring measures should be available during infusion.

Risk of Antibody Development: Since Lumizyme is a protein, it is the possible that patients receiving it develop antibodies. Some patients who develop high IgG antibody levels that last for a while may have reduced response to Lumizyme. Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter.


The most frequently reported adverse reactions during Lumizyme studies in patients were allergy reactions and included: anaphylaxis, rash, fever, flushing/feeling hot, hives, headache, excessive sweating, nausea, cough, less oxygen in the blood, fast heart rate, rapid breathing, chest discomfort, dizziness, muscle twitching, agitation, bluish or purple skin, redness of skin, high blood pressure/increased blood pressure, facial paleness, chills, tremor, vomiting, fatigue, and muscle pain.


If you are pregnant, you should use Lumizyme only if your doctor has determined that its use outweighs any risks to your unborn child.

To report suspected adverse reactions, contact Sanofi Genzyme at 1-800-745-4447 or FDA at 1-800-FDA-1088 or

Please see the Full Prescribing Information for complete details, including boxed WARNING.